2017 (v1)
Publication
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma
Natalizumab (NTZ) is a monoclonal antibody targeting the α4β1 integrin (CD49d/CD29), very late antigen-4 (VLA-4), which is approved for treatment of relapsing-remitting multiple sclerosis (RR-MS). A possible association between NTZ treatment and a higher risk of melanoma is under debate. Natural Killer (NK) cells, which express VLA-4, represent...
Uploaded on: April 14, 2023